Bemosuzumab

ApprovedMonoclonal antibody

FFujian Medical University

Bemosuzumab is one of 40 small molecule programs targeting Thyroid Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CancerActive, not recruiting

Thyroid CancerApproved

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

12 2

Koselugo

AstraZeneca

Phase 3

3 3

Glucophage

EMD Serono

Phase 3

2 4

Yervoy

Bristol-Myers Squibb

Phase 2

2 5

Mektovi

Pfizer

Phase 2

1 6

Stivarga

Bayer

Phase 2

1 7

Actos

Takeda

Phase 2

1 8

Cotellic

Roche

Phase 2

1 9

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 10

Droxia

TTheravia

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalNot yet recruiting

Thyroid Cancer

NCT07010393

Clinical

Trials by Indication[1]

Thyroid Cancer1 trial

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not yet recruiting·FFujian Medical University·Phase 4·NCT07010393·335 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bemosuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bemosuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bemosuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Approved[1]
Company: FFujian Medical University

Bemosuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Thyroid Cancer1 trial

References

Drug Info

Quick Facts

Related News